SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Erlanson M.)
 

Search: WFRF:(Erlanson M.) > Dose-densified chem...

Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/follicular grade 3 lymphoma patients : results of a phase II Nordic Lymphoma Group study

Holte, H. (author)
Leppa, S. (author)
Bjorkholm, M. (author)
Karolinska Institutet
show more...
Fluge, O. (author)
Jyrkkio, S. (author)
Delabie, J. (author)
Sundström, Christer (author)
Uppsala universitet,Molekylär och morfologisk patologi
Karjalainen-Lindsberg, M. -L (author)
Eriksson, Mikael (author)
Lund University,Lunds universitet,Bröstcancer-genetik,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Breastcancer-genetics,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine
Kolstad, A. (author)
Fossa, A. (author)
Ostenstad, B. (author)
Lofvenberg, E. (author)
Nordstrom, M. (author)
Janes, R. (author)
Pedersen, L. M. (author)
Anderson, Harald (author)
Lund University,Lunds universitet,Medicinsk onkologi,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Medical oncology,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine
Jerkeman, Mats (author)
Lund University,Lunds universitet,Bröstcancer-genetik,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Breastcancer-genetics,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine
Erlanson, Martin (author)
Umeå universitet,Onkologi
show less...
 (creator_code:org_t)
Elsevier BV, 2013
2013
English.
In: Annals of Oncology. - : Elsevier BV. - 0923-7534 .- 1569-8041. ; 24:5, s. 1385-1392
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • Background: Many patients with aggressive B-cell lymphomas and high clinical risk score still die of lymphoma after conventional R-CHOP chemoimmunotherapy. We hypothesized that intensified chemoimmunotherapy including systemic central nervous system (CNS) prophylaxis improves outcome and reduces the incidence of CNS-related events. Patients and methods: Inclusion criteria were age 18-65 years, primary diffuse large B-cell lymphoma or grade III follicular lymphoma without clinical signs of CNS disease and negative cerebrospinal fluid cytology, age-adjusted International Prognostic Index 2-3 and WHO performance score 0-3. Treatment consisted of six courses of R-CHOEP-14 followed by a course of high-dose cytarabine and a course of high-dose methotrexate. Primary end point was failure-free survival (FFS) at 3 years. Results: A total of 156 eligible patients with a median age of 54 years (range 20-64) were included. Three toxic deaths were observed. Three-year overall survival (OS) and FFS rates (median observation time 52 months for survivors) were 81% and 65%, respectively. Seven patients experienced CNS relapse, all within 6 months. Conclusions: The results are promising with favorable 3-year OS and FFS rates, a low toxic death rate and a lower than expected number of CNS events. CNS progression might be further reduced by earlier CNS prophylaxis. CinicalTrials.gov.identifier: NCT01502982.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Cancer and Oncology (hsv//eng)

Keyword

age-adjusted IPI
central nervous system
diffuse large B-cell lymphoma
intensive chemotherapy
prophylaxis
age-adjusted IPI
central nervous system
diffuse large B-cell lymphoma
intensive chemotherapy
prophylaxis

Publication and Content Type

ref (subject category)
art (subject category)

Find in a library

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view